MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Summary
MannKind (Nasdaq: MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference in New York. Chief Financial Officer Chris Prentiss and Dr. Wasim Fares, Therapeutic Area Head for Orphan Lung Diseases, will present during a fireside chat on Wednesday, September 18 at 1:20 p.m. Eastern Time.
The presentation will be accessible via a live audio webcast on MannKind's website, with a recorded version available for approximately 30 days after the event. This conference provides an opportunity for MannKind to share updates on their innovative therapeutic products and connect with healthcare industry professionals.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
In the trading session that priced this news, MNKD gained 1.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Financial Officer Chris Prentiss and Dr. Wasim Fares Therapeutic Area Head, Orphan Lung Diseases, will share updates during a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York.
The fireside chat will take place on Wednesday, September 18 beginning at 1:20 p.m. Eastern Time. A link to the live audio webcast of the session will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. An archived, recorded version will also be available on the website for approximately 30 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
MANNKIND is a registered trademark of MannKind Corporation.
